The molecular basis of prostate cancer

British Journal of Hospital Medicine

Volumn 66, Issue 11, 2005, Pages 612-616

  Olsson, A Yvonne ^a   Cooper, Colin S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; GLI PROTEIN; HISTONE; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RETINOBLASTOMA PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; WNT PROTEIN;

APOPTOSIS; DNA REPAIR; GENETICS; HUMAN; MALE; METABOLISM; MITOSIS; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; REVIEW;

1-PHOSPHATIDYLINOSITOL 3-KINASE; APOPTOSIS; DNA REPAIR; HEDGEHOG PROTEINS; HISTONES; HUMANS; MALE; MITOSIS; ONCOGENE PROTEINS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; RETINOBLASTOMA PROTEIN; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; WNT PROTEINS;

EID: 33645505764     PISSN: 17508460     EISSN: None     Source Type: Journal    
DOI: 10.12968/hmed.2005.66.11.20021     Document Type: Conference Paper

References (19)

1. Berezovskaya O, Schimmer AD, Glinskii AB et al (2005) Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res 65: 2378-86
2. Chen CD, Welsbie DS, Tran C et al (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-9
3. Cher ML, Bova GS, Moore DH et al (1996) Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 56: 3091-102
4. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA, Tindall DJ (2003) p300 in prostate cancer proliferation and progression. Cancer Res 63: 7638-40
5. Farmer H, McCabe N, Lord CJ et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-21
6. Foster CS, Falconer A, Dodson AR et al (2004) Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 23: 5871-979
7. Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S, Shiina H (2004) Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol 171: 1855-60
8. Maddison LA, Sutherland BW, Barrios RJ, Greenberg NM (2004) Conditional deletion of Rb causes early stage prostate cancer. Cancer Res 64: 6018-25
9. Malumbres M, Barbacid M (2001) To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1: 222-31
10. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL (2004) HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6: 517-27
11. Reagan-Shaw S, Ahmad N (2005) Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancet cells: implications for the treatment of prostate cancer. FASEB J 19: 611-13
12. Sanchez P, Hernandez AM, Stecca B et al (2004) Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc Natl Acad Sci USA 101: 12561-6
13. Sanchez P, Clement V, Altaba A (2005) Therapeutic targeting of the Hedgehog-GLI pathway in prostate cancet. Cancer Res 65: 2990-2
14. Sansal I, Sellers WR (2004) The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22: 2954-63
15. Seligson DB, Horvath S, Shi T et al (2005) Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435: 1262-6
16. Varambally S, Dhanasekaran SM, Zhou M et al (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-9
17. Verras M, Sun Z (2005) Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett Epub (in press)
18. Vogelstein B, Kinzler KW (2004) Cancer genes and the pathways they control. Nat Med 10: 789-99
19. Zhang M, Latham DE, Delaney MA, Chakravarti A (2005) Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 24: 2474-82